SAN DIEGO, Nov. 20, 2014 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional
biology company focused on delivering breakthrough 3D bioprinting
technology, has been invited to present at the 26th Annual Piper
Jaffray Healthcare Conference, which will be held in New York December 2-3,
2014.
Organovo's Chairman and Chief Executive Officer, Keith Murphy, will be presenting on Tuesday, December 2, at 4:30pm ET.
The goal of Piper Jaffray's 26th
Annual Healthcare Conference is to bring together key industry
executives, investors and Piper professionals to provide multiple
perspectives, investigate critical trends and identify the leaders
in the markets that are driving our economy. The conference
will be held at The New York Palace Hotel, 455 Madison Avenue,
New York, NY 10022.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for use in medical research and therapeutic applications.
The Company develops 3D human disease models through internal
development and in collaboration with pharmaceutical and academic
partners. Organovo's 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be
developed faster and at lower cost. The company recently launched
its initial product of the planned exVive3DTM portfolio offering, a
3D Human Liver Tissue for use in Toxicology and other preclinical
drug testing. Additional products, including a 3D Kidney Model, are
in development with anticipated release for use in the latter half
of calendar year 2016. Furthermore, the company actively
conducts early research on specific tissues for therapeutic use in
direct surgical applications. In addition to numerous scientific
publications, the Company's technology has been featured in The
Wall Street Journal, Time Magazine, The Economist, and numerous
others. Organovo is changing the shape of medical research and
practice. Learn more at www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed
with the SEC on November 7, 2014, as
well as our other filings with the SEC. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.
